Found 114 articles for: "treatment"
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreExpert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema
March 2026 | Volume 25 | Issue 3 | Original Article | 228 | Copyright © March 2026
Background: Chronic hand eczema (CHE) is a common, heterogeneous inflammatory skin disease associated with substantial symptom burden, impaired hand function, reduced quality of ...
Read MoreTopical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants
January 2026 | Volume 25 | Issue 1 | Original Article | 67 | Copyright © January 2026
Background: Topical efinaconazole 10% solution has demonstrated efficacy and safety in two phase 3 trials of onychomycosis. As clinical data for onychomycosis treatments are limi...
Read MoreA Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma
January 2026 | Volume 25 | Issue 1 | Original Article | 25 | Copyright © January 2026
Background: Previous studies have documented the capacity of malassezin to brighten the skin. It represents a novel agent for the treatment of hyperpigmentation.GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities
December 2025 | Volume 24 | Issue 12 | Original Article | 1174 | Copyright © December 2025
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with many comorbidities, including obesity, diabetes, cardiovascular risk factors, me...
Read MoreAn Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa
December 2025 | Volume 24 | Issue 12 | Original Article | 1246 | Copyright © December 2025
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with obesity and metabolic dysregulation. Current therapies yield variable benefits and do ...
Read MorePerspectives and Practice Patterns of Dermatologists Using Laser Hair Removal for Hidradenitis Suppurativa
December 2025 | Volume 24 | Issue 12 | Editorials | e71 | Copyright © December 2025
The Current Landscape of Treatment of Warts
December 2025 | Volume 24 | Issue 12 | Original Article | 1208 | Copyright © December 2025
Warts have bothered people since the early Greek and Roman empires.5 For centuries, people have studied causes of and treatments for these irritating tumors. In recent history, treatme...
Read MoreResolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
December 2025 | Volume 24 | Issue 12 | Case Reports | 1252 | Copyright © December 2025
Introduction: Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to tre...
Read MoreScar Wars: A Review of Topical Scar Therapies
December 2025 | Volume 24 | Issue 12 | Features | 1265 | Copyright © December 2025
Maximizing a Focused Vitiligo Patient Visit: A Practical Approach
December 2025 | Volume 24 | Issue 12 | Features | 1256 | Copyright © December 2025
Pyoderma Gangrenosum Following Total Colectomy for Ulcerative Colitis
December 2025 | Volume 24 | Issue 12 | Case Reports | 1254 | Copyright © December 2025
NECASA II: A Practical Algorithm Integrating Skincare in the Management of Adult Female Acne in the Nordic European Countries
November 2025 | Volume 24 | Issue 11 | Original Article | 1094 | Copyright © November 2025
Background: Adult female acne presents challenges, including increased prevalence, distinct clinical manifestations, heightened skin sensitivity, treatment-related intolerance, a...
Read MoreCaffeine Supplementation and Hair: A Systematic Review
November 2025 | Volume 24 | Issue 11 | Original Article | 1070 | Copyright © November 2025
Background: While caffeine has been proposed to stimulate hair growth, its safety and efficacy remain unclear. This systematic review evaluates the effects of caffeine interventi...
Read MoreTreatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib
November 2025 | Volume 24 | Issue 11 | Case Reports | 1138 | Copyright © November 2025
Primary biliary cholangitis (PBC) can present with overlapping features of limited systemic sclerosis, commonly known as calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, a...
Read MoreManagement of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream
November 2025 | Volume 24 | Issue 11 | Case Reports | 1141 | Copyright © November 2025
Introduction: Benign Familial Pemphigus (Hailey-Hailey Disease [HHD]) is a rare chronic condition, with treatments focusing on managing disease symptoms.Case...
Read MoreAssessing Cutibacterium Acnes Susceptibility With Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel Use: Six-Month Analysis
November 2025 | Volume 24 | Issue 11 | Original Article | 1106 | Copyright © November 2025
Background: The only approved triple-combination acne treatment – clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel - demonstrated efficacy/safety ...
Read MoreReal-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months
October 2025 | Volume 24 | Issue 10 | Original Article | 996 | Copyright © October 2025
Background: Dupilumab has demonstrated benefits in patients with atopic dermatitis (AD), but there is limited information on real-world rates of dupilumab persistence and supplem...
Read MoreSkin Barrier Benefits of a Natural Moisturizing Factor and Lipids-Based Moisturizer for Clinically Sensitive Skin
October 2025 | Volume 24 | Issue 10 | Original Article | 1029 | Copyright © October 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
